Bulletin
Investor Alert

May 27, 2020, 9:49 a.m. EDT

Hepatitis B Vaccine Market Worth Nearly $2,158.1 Mn by 2027

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

or Cancel Already have a watchlist? Log In

May 27, 2020 (Market Prediction via COMTEX) -- The global Hepatitis B Vaccine Market is estimated to grow at a healthy CAGR of over 5.8% during the forecast period 2020 to 2027 and reach a valuation of over US$ 2,158.1 Mn. The market report provides an analysis of the global Hepatitis B Vaccine Market for the period 2016-2027, wherein 2020 to 2027 is the forecast period and 2019 is considered as the base year.

In 2018, North America held the major share of the global market for the Hepatitis B vaccine and the region is also anticipated to maintain its dominance during the forecast period from 2019 to 2026. The region is primarily gaining growth owing to the increasing number of cases affected by the Hepatitis B virus. The region is also having potential share due to its advanced healthcare infrastructure. According to the American Academy of Family Physicians (AAFP), around 1.25 million Americans had chronic hepatitis B in the year 2004 and according to the WHO 2019 estimates for America region, 0.7% of the population is infected with the Hepatitis B virus.

Download FREE SAMPLE PDF (Including Full TOC, Table & Figures)@ https://www.acumenresearchandconsulting.com/request-sample/1661

The combination vaccines segment accounted for the major share by type in the hepatitis B vaccine market due to its characteristics of protection against multiple causative agents. The combination vaccine also decreases the cost of packaging, which is administered for individual vaccines and is also contributing to the segment market growth. For instance, a combination vaccine name Twinrix can protect against both hepatitis B and hepatitis A. Some of the other combination vaccines names include Ambirix, Comvax, and Hexacima/ Hexyon.

On the basis of dose, the 3-Dose Schedule segment is dominating the market with a major share. The segment is particularly gaining positive growth because it is prominently recommended for the infants due to the high risk of the virus which can develop a lifelong infection if they are exposed to the hepatitis B virus. Furthermore, VBI Vaccines Inc. announced the company's abstract based on the 3-Dose hepatitis B (HepB) vaccine, which is selected for a late-breaker oral presentation at IDWeek 2019, in Washington, D.C. Moreover, 2-dose schedule hepatitis B vaccine is projected to be the fastest growing segment over the estimated period. HEPLISAV-B is the first and only 2-dose hepatitis B vaccine offered by Dynavax Technologies Corporation is approved by U.S. Food and Drug Administration (FDA).

Hospitals segment by end-user exhibited maximum growth in the year 2018 and the segment is also anticipated to continue with the same pace over the forecast period 2019 to 2026. The segment is having potential share owing to the large volume of product sales in the hospitals. The first dose of the Hepatitis B vaccine is recommended to be administered before the discharge of infants from the hospitals, which is supporting the segment growth.

Related Reports

  • Vaccines Market – The global market is expected to grow at a CAGR of around 6.4% from forecast period 2019 to 2026 and to reach the market value of around US$ 55.2 billion by 2026.

  • Meningococcal Vaccines Market – The global market value is estimated to hit USD 9.37 billion by 2026 and expected to grow at a CAGR of 12.3% over period 2019 to 2026.

  • Biopharmaceutical CMO & CRO Market – The global market is expected to grow at noteworthy CAGR around 7.5 % throughout the forecast period and reach around US$ 39 billion by 2026.

Some of the leading competitors are Sanofi, Merck & Co., Inc., GlaxoSmithKline plc, Indian Immunologicals Limited, LG Chem, KM Biologics, Dynavax Technologies, and Janssen Pharmaceuticals. Hepatitis B Vaccine companies have announced mergers and acquisitions to expand their position in the Hepatitis B Vaccine industry. Major players are also moving into new regions with advanced technologies to treat hepatitis B virus-infected people better.

Market Segmentation

Market By Type

  • Single Antigen Hepatitis B Vaccine

  • Combination Vaccines

Market By Dose

  • 3-Dose Schedule

  • 2-Dose Schedule

  • Alternate Schedule

Market By End User

  • Hospitals

  • Clinics

  • Doctor Offices

  • Others (Medical Camp, Local Health Department)

(Regional Output, Demand & Forecast by Countries)

  • North America (USA and Canada)

  • Europe (UK, Germany, France, Spain and Rest of Europe)

  • Asia Pacific(China, Japan, India, Australia, South Korea and Rest of Asia-Pacific)

  • Latin America(Mexico, Brazil and Rest of Latin America)

  • Middle East and Africa(GCC, South Africa and Rest of MEA).

1 2
This Story has 0 Comments
Be the first to comment

Story Conversation

Commenting FAQs »
Link to MarketWatch's Slice.